Home / Health / New Diabetes Drugs Show Promising Trial Results
New Diabetes Drugs Show Promising Trial Results
8 Jun
Summary
- Roche's acmopatide improved glucose control and reduced weight in type 1 diabetes.
- MannKind's Afrezza showed effective glycemic control and patient satisfaction in children.
- Amgen's Repatha significantly lowered LDL-C in high-risk diabetes patients.
The American Diabetes Association (ADA) conference 2026 has showcased major advancements in diabetes care, with new data presented on treatments for type 1 and type 2 diabetes. Roche reported positive Phase II results for acmopatide, a potential incretin therapy for type 1 diabetes, which improved blood glucose management, aided weight loss, and reduced insulin needs.
Further promising findings emerged for MannKind's inhaled insulin, Afrezza. Following its recent FDA approval for pediatric use, post-hoc analysis from the INHALE-1 study indicated greater treatment satisfaction among children and adolescents compared to rapid-acting insulin analogues, with similar glycemic outcomes.
In the realm of cardiovascular risk reduction, Amgen presented data from the VESALIUS-CV trial. Repatha, when added to existing therapies, significantly reduced the risk of major adverse cardiovascular events in high-risk diabetic patients with elevated LDL-C.
Additionally, Eli Lilly shared detailed efficacy and safety data for retatrutide in type 2 diabetes. The TRANSCEND-T2D-1 study revealed substantial reductions in triglycerides, non-HDL cholesterol, blood pressure, and waist circumference, with a high percentage of patients achieving target A1C levels.
